StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Sunday morning. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 1.9 %

NYSE NBY opened at $0.71 on Friday. The company has a market cap of $3.50 million, a PE ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $11.45. The stock’s 50-day moving average price is $0.66 and its two-hundred day moving average price is $1.55.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.